Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationSentinel · blood-based contexts
Sentinel Blood
Continuous monitoring for blood-based and haematological cancers on active treatment, following disease-specific markers over time.
Sentinel Blood
Monitoring for blood-based cancers
Sentinel Blood follows disease-specific molecular markers over time, so your team can see whether treatment is working and respond early if the picture changes.
It tracks condition-appropriate markers, for example NPM1, BCR-ABL1 or B-cell clonality signals where relevant, each result read against your baseline.
How it works
- Step 1Baseline
Establish your molecular starting point.
- Step 2Scheduled draws
Monitoring on your chosen Track: 2, 4 or 6 per year.
- Step 3Trend interpretation
The engine reads direction of travel, not one value.
- Step 4Clinician review
A meaningful change triggers KPCIRC review and a plan.
Honest limits
Monitoring shows trends and can flag change early, but it does not replace your haematologist’s assessment or scheduled testing. No single result should be read in isolation, and decisions are made by your clinical team.
Being clear about our limits
What we do and do not do
What we DO
- Track whether active treatment is working over time
- Catch resistance and molecular progression early
- Trigger KPCIRC review and a timely next-line plan
- Match cadence to need through Track 2, 4 or 6
What we DON’T do
- Diagnose or switch therapy on its own, KPCIRC decides
- Detect every change, since some tumours shed little ctDNA
- Replace your scans and oncologist review
- Guarantee that an earlier switch will change the outcome
Plain-language glossary (5 terms)
| Term | What it means |
|---|---|
| ctDNA | Circulating tumour DNA, tumour fragments a blood test can read over time. |
| Resistance mutation | A new change that lets a cancer escape a treatment that was working. |
| Molecular progression | A rise in ctDNA signalling the cancer is advancing. |
| VAF | Variant allele frequency, how much of a mutation is present, tracked over time. |
| Serial monitoring | Repeat testing at intervals to watch the trend, not one snapshot. |
Important information and regulatory status
Sentinel Blood is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.
- A result is not a diagnosis and does not by itself decide treatment.
- A “not detected” result does not rule out cancer or a genetic change.
- Not all cancers release enough DNA into blood to be detected.
- We cannot guarantee that a medicine will be available, approved, covered or effective.
- Collection kits are for qualified phlebotomists. They are not for self-testing.
- Confirmatory testing may be required.
Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner holding NABL (ISO 15189), CAP and CLIA accreditation, following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
Take the next step
Three ways forward. Pick the one that fits today.
Begin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal